Viatris Inc. (VTRS) Stock Grade

About Viatris Inc.'s fundamentals

Viatris is a $21.3 billion specialty and generic pharmaceutical company currently operating at a loss, with a net margin of -24.6% and revenue declining 3.0% year-over-year. Despite reporting negative net income in its latest annual statement, the company generated positive free cash flow, suggesting operational cash generation despite accounting losses. The company offers a 3.8% dividend yield, which it appears to be supporting through cash flow rather than current earnings.